Short Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Drops By 20.8%

Iterum Therapeutics plc (NASDAQ:ITRM) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 1,790,000 shares, a drop of 20.8% from the December 15th total of 2,260,000 shares. Approximately 6.7% of the company’s shares are sold short. Based on an average daily trading volume, of 2,880,000 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Iterum Therapeutics stock. XTX Topco Ltd bought a new position in shares of Iterum Therapeutics plc (NASDAQ:ITRM) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 33,040 shares of the company’s stock, valued at approximately $36,000. XTX Topco Ltd owned approximately 0.15% of Iterum Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 9.21% of the company’s stock.

Iterum Therapeutics Stock Performance

Shares of Iterum Therapeutics stock traded down $0.06 on Thursday, reaching $1.54. The company had a trading volume of 607,567 shares, compared to its average volume of 598,002. The firm’s 50 day moving average price is $1.85 and its two-hundred day moving average price is $1.41. Iterum Therapeutics has a 52-week low of $0.81 and a 52-week high of $3.02. The firm has a market cap of $42.38 million, a PE ratio of -0.77 and a beta of 2.33.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.